ALMR (Alamar Biosciences) YoY EBITDA Growth: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALMR Alamar Biosciences Inc ALMR
12 GF Score
Price $34.85
! 1 Warning Sign
View Full Analysis

What is Alamar Biosciences YoY EBITDA Growth?

Alamar Biosciences ALMR +8.84% 12 YoY EBITDA Growth is 0.00% as of Jun. 2026. GuruFocus rates ALMR with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Alamar Biosciences's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 0.00%.

Alamar Biosciences's EBITDA per Share for the three months ended in Jun. 2026 was $-0.17.

Alamar Biosciences YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Alamar Biosciences's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alamar Biosciences YoY EBITDA Growth Chart

Alamar Biosciences Annual Data
Trend Dec24 Dec25
YoY EBITDA Growth
0.00 40.45

Alamar Biosciences Quarterly Data
Mar25 Jun25 Mar26 Jun26
YoY EBITDA Growth 0.00 0.00 0.00 0.00
ALMR
12GF Score
Alamar Biosciences Inc ALMR
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alamar Biosciences YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Alamar Biosciences's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.374--0.628)/ | -0.628 |
=40.45 %

Alamar Biosciences's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: . 20 )) / | EBITDA per Share (Q: . 20 )) |
=(-0.172-)/ | |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 0.00% mean?
Alamar Biosciences (ALMR) has a YoY EBITDA Growth of 0.00% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Alamar Biosciences and its competitors.
Is Alamar Biosciences' YoY EBITDA Growth too high?
Alamar Biosciences' current YoY EBITDA Growth is 0.00%. Overall, Alamar Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alamar Biosciences' YoY EBITDA Growth compare to ESTA and NVCR?
Alamar Biosciences' YoY EBITDA Growth of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Alamar Biosciences and its competitors. Alamar Biosciences's current YoY EBITDA Growth is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alamar Biosciences stock overvalued right now?
Alamar Biosciences (ALMR) has a current YoY EBITDA Growth of 0.00%. The current YoY EBITDA Growth is 0.00%. Alamar Biosciences' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Alamar Biosciences (ALMR), the current YoY EBITDA Growth is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alamar Biosciences Business Description

Address 47071 Bayside Parkway, Fremont, CA, USA, 94538
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
12GF Score

Get the complete analysis for ALMR

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.85
Price